Crohn Disease
Conditions
Keywords
Inflammatory Bowel Diseases, Crohn's Disease, Immunonutrition
Brief summary
This is an interventional randomized ope-label two-arm trial on the peri-operative use of immunonutrition in Crohn's Disease (CD) patients undergoing colorectal elective surgery.The aim of the trial is to assess the effectiveness of immunonutrition therapy in decreasing the rate of post-operative infective complications and 6 months endoscopic disease recurrence.
Detailed description
Crohn's Disease (CD) patients undergoing abdominal surgery are at high risk to develop post-operative surgical and medical infective complications. Infective complications affect almost 24% of patients. Post-surgical disease recurrence afflicts 35-85% of CD patients in the first year after surgery. Immunonutrition has been successfully applied to surgical patients in several randomized trials, demonstrating a decreased rate of post-operative infective complications. The aim of the study is to compare the incidence of surgical and medical post-operative infective complications and six months endoscopic and clinical disease recurrence (DR) in CD patients receiving immunonutrition in the peri-operative setting compared to patients treated as for standard of care.
Interventions
OTHERStandard of Care
Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
DIETARY_SUPPLEMENTImmunonutrition
Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
Sponsors
Istituto Clinico Humanitas
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients \> 18 years old, females or males; * Established Crohn's Disease at the time of surgery indication; * Patients scheduled for elective open or minimally invasive bowel resection or strictureplasty; * Patients planned for concomitant perianal surgery for CD-related perianal disease can be included in the study.
Exclusion criteria
* Patients \< 18 years old; * Pregnant or breastfeeding women; * Diagnosis of undetermined colitis; * Concomitant diagnosis of malignancy; * Established malnutrition, according to clinical definition, requiring nutritional intervention; * Patients with more than two criteria for high risk of recurrence among the following: previous abdominal resection, penetrating disease phenotype or active smoking; * Any condition that, in the opinion of the investigator, can interfere with the consent procedure or the conduction of the trial; * Patients known to have allergic history to any component of the investigational product; * Patient with liver and kidney dysfunction (alanine aminotransferase ALT ≥ 2 times the upper limit of normal; total bilirubin TBIL ≥ 2 times the upper limit of normal; creatinine Cr ≥ 2 times the upper limit of normal); * Patients diagnosed with diabetes or fasting blood glucose≥ 10mmol/L; * Planned recovery shorter than 48 hours; * Surgery in emergency setting; * Any concomitant surgery not related to CD or perianal CD.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Post-operative infective complications rate | 30 days post-operatively | Post-operative infective complications rate (including intra-abdominal septic complications, surgical site infections and medical inflections) will be evaluated with clinical, radiological and molecular analysis |
| 6 months endoscopic recurrence | 6 months post-operatively | Endoscopic recurrence will be evaluated through colonoscopy with or without biopsies and Rutgeert score. Rutgeert score is an endoscopic risk score intended to predict disease recurrence: it is calculated depending on the number and type of intestinal lesions and consists of five level of disease recurrence risk, from 0 (endoscopic remission) to 4 (advanced disease recurrence). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6 months nutritional status | 6 months post-operatively | Nutritional status will be evaluated through the Malnutrition Universal Screening Tool (MUST). MUST consists of three different levels, generating a risk predictor ranging from 0 (low risk) to 2 (high risk), considering the calculated Body Mass Index (BMI), the unintentional weight loss and the pathological conditions of the patient. |
| 30 days quality of life | 30 days post-operatively | Quality of Life will be evaluated trhough the Short-Inflammatory Bowel Disease Quality of Life questionnaire (S-IBDQoL), which is 10-item questionnaire. All items are reported in a 7 point scale, from all of the time to none of the time (1 = poor health; 7 = good health). |
| 90 days quality of life | 90 days post-operatively | Quality of Life will be evaluated trhough the Short-Inflammatory Bowel Disease Quality of Life questionnaire (S-IBDQoL), which is 10-item questionnaire. All items are reported in a 7 point scale, from all of the time to none of the time (1 = poor health; 7 = good health). |
| 6 months quality of life | 6 months post-operatively | Quality of Life will be evaluated trhough the Short-Inflammatory Bowel Disease Quality of Life questionnaire (S-IBDQoL), which is 10-item questionnaire. All items are reported in a 7 point scale, from all of the time to none of the time (1 = poor health; 7 = good health). |
Contacts
Primary ContactAnnalisa Maroli, PhD
Backup ContactLara Monti, MS
Outcome results
None listed